Filtered By:
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 1360 results found since Jan 2013.

Effect of drug use in the treatment of acute ischemic stroke: A scoping review
CONCLUSION: Evidence for thrombolytic and thrombectomy treatment in drug users remains limited. Controlled studies are needed to examine complication profile and outcomes following thrombolytic and thrombectomy treatment in this population.PMID:36128166 | PMC:PMC9479649 | DOI:10.25259/SNI_561_2022
Source: Surgical Neurology International - September 21, 2022 Category: Neurosurgery Authors: Nisha Dabhi Panagiotis Mastorakos Jennifer D Sokolowski Ryan T Kellogg Min S Park Source Type: research

Successful thrombolytic therapy is associated with increased granulocyte CD15 expression and reduced stroke ‐induced immunosuppression
ConclusionsOur current results indicate that TT may not only acutely reduce the systemic inflammatory response following stroke but may also play a role in reversing SIIS at a later stage following the insult, as reflected by the higher expression of the CD15 marker on granulocytes following successful TT.
Source: Brain and Behavior - September 16, 2022 Category: Neurology Authors: Katalin Anna B éres‐Molnár, Ágnes Czeti, Ferenc Takács, Gábor Barna, Dániel Kis, Gabriella Róka, András Folyovich, Gergely Toldi Tags: ORIGINAL ARTICLE Source Type: research

Moving from traditional to more advanced treatments in stroke care is cost-effective: A case study from Greece
Ischemic stroke (IS) is one of the leading causes of mortality and disability,1, 2 with the economic burden of post-stroke care being substantial.1, 2 After incidence of IS, the following effective treatments have been found to significantly improve survival and quality of life: (a) treatment in specialized centres (Stroke Units; SU), (b) use of intravenous thrombolytic therapy (IVT), (c) use of endovascular thrombectomy (EVT) for patients with large vessel occlusions (LVO) and (d) rehabilitation.
Source: Journal of Stroke and Cerebrovascular Diseases - September 10, 2022 Category: Neurology Authors: Konstantinos Dimitriadis, Ilias Kyriopoulos, Georgios Tsivgoulis, Konstantinos Vemmos, Wolfgang G. Kunz, Elias Mossialos Source Type: research

Molecules, Vol. 27, Pages 5488: The Effect of a New N-hetero Cycle Derivative on Behavior and Inflammation against the Background of Ischemic Stroke
Kiseleva Vadim V. Negrebetsky Yuri I. Baukov Ischemic stroke triggers a whole cascade of pathological changes in the brain, one of which is postischemic inflammation. Since in such cases thrombolytic therapy is often not possible, methods that modulate inflammation and affect microglia become particularly interesting. We synthesized 3-(2-oxo-4-phenylpyrrolidin-1-yl)propane-1-sulfonate calcium(II) (Compound 4) and studied its anti-inflammatory activity in in vitro and in vivo models of inflammation and ischemia. Macrophage cell line RAW 264.7 was treated with lipopolysaccharides (LPS) and Compound 4 at various dosa...
Source: Molecules - August 26, 2022 Category: Chemistry Authors: Denis A. Borozdenko Tatiana A. Shmigol Aiarpi A. Ezdoglian Darya I. Gonchar Natalia. Y. Karpechenko Dmitri N. Lyakhmun Anastasia D. Shagina Elvira A. Cherkashova Daria D. Namestnikova Ilya L. Gubskiy Anastasia A. Chernysheva Nina M. Kiseleva Vadim V. Negr Tags: Article Source Type: research

The potential role of insulin resistance in predicting outcome from intravenous thrombolytic therapy
ConclusionInsulin resistance and metabolic syndrome were associated with worse functional outcomes in non-diabetic stroke patients after receiving rt-PA.
Source: Acta Neurologica Belgica - August 20, 2022 Category: Neurology Source Type: research

Remote Ischemic Conditioning —Feasible and Potentially Beneficial for Ischemic Stroke
Stroke is the second leading cause of death and disability in the world. In 1996, tissue plasminogen activator (tPA) was approved by the US Food and Drug Administration and remains the only approved pharmacologic agent for treatment of ischemic stroke in the US. In 2015, mechanical thrombectomy was shown to be beneficial for large vessel occlusion ischemic stroke, although 50% of patients treated with mechanical thrombectomy remain disabled at 3 months. Due to short time windows for thrombolytic therapy administration and the stroke system infrastructure needed for mechanical thrombectomy, these reperfusion therapies are a...
Source: JAMA - August 16, 2022 Category: General Medicine Source Type: research

Synthetic role of miR-411-5p and CT perfusion information in predicting clinical outcomes after thrombolysis in acute cerebral infarction
ConclusionmiR-411-5p is increased by thrombolytic therapy in ACI patients, and miR-411-5p, CBF and CBV may serve as independent biomarkers for predicting short- and long-term prognosis following intravenous thrombolysis in ACI patients.
Source: Acta Neurologica Belgica - August 6, 2022 Category: Neurology Source Type: research

The influence of unexpected early termination of intravenous rt-PA treatment on clinical outcome in acute ischemic stroke patients
ConclusionSubjective wishes of family members and persistently elevated blood pressure may be the main causes of early termination of thrombolysis, and the 3-month prognosis of patients could be adversely affected by early termination of thrombolytic therapy and cumulative dosage of rt-PA. Certain measures, such as popularizing thrombolytic health education and optimizing blood pressure management before and during thrombolysis, may be helpful for the normal operation of intravenous thrombolysis.
Source: Acta Neurologica Belgica - August 2, 2022 Category: Neurology Source Type: research

Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients
ConclusionsThe use of a blood biomarker test to guide pre-hospital thrombolysis is cost-effective compared with standard hospital care in patients with ischemic stroke.
Source: The European Journal of Health Economics - July 27, 2022 Category: Health Management Source Type: research

E-048 Antithrombotics for emergent stenting in acute stroke
ConclusionTirofiban continuous infusion is a safe and possibly effective strategy for emergent stenting in acute ischemic stroke.Disclosures S. Lahoti: None. K. Limaye: None. C. Zevallos: None. K. Dlouhy: None. M. Hayakawa: None. E. Samaniego: None. D. Hasan: None. S. Ortega: 2; C; Medtronic, Stryker Neurovascular, Microvention. C. Derdeyn: 1; C; Siemens Healthineers. 4; C; Euphrates Vascular, Inc. 6; C; DSMB: Penumbra (MIND), NoNO (ESCAPE NA1 and FRONTIER).
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lahoti, S., Limaye, K., Zevallos, C., Dlouhy, K., Hayakawa, M., Samaniego, E., Hasan, D., Ortega, S., Derdeyn, C. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

Type of anaesthesia for acute ischaemic stroke endovascular treatment
CONCLUSIONS: In early outcomes, general anaesthesia improves target artery revascularisation compared to non-general anaesthesia with moderate-certainty evidence. General anaesthesia may improve adverse events (haemodynamic instability) compared to non-general anaesthesia with low-certainty evidence. We found no evidence of a difference in neurological impairment, stroke-related mortality, all intracranial haemorrhage and haemodynamic instability adverse events between groups with low-certainty evidence. We are uncertain whether general anaesthesia improves functional outcomes and time to revascularisation because the cert...
Source: Cochrane Database of Systematic Reviews - July 20, 2022 Category: General Medicine Authors: Renato Tosello Rachel Riera Giuliano Tosello Caroline Nb Clezar Jorge E Amorim Vladimir Vasconcelos Benedito B Joao Ronald Lg Flumignan Source Type: research